HUTCHMED (00013) announces annual performance with a net profit attributable to shareholders of $457 million USD, a year-on-year increase of 1111.03%.

HUTCHMED (00013) released its full-year performance for 2025, with total revenue of $549 million, a decrease of 12.96% year-on-year; shareholder's profit attributable to equity holders reached $457 million, an increase of 1111.03% year-on-year; basic earnings per share of $0.53. Dr. Dan Eldar, non-executive chairman of HUTCHMED, stated: "Our team's scientific expertise in innovative drug research, combined with the assistance of advanced artificial intelligence (AI) tools, has positioned HUTCHMED at the forefront of exploring novel treatment mechanisms. Leveraging this leading position, we continue to actively explore new technologies, products, and targets to enrich our product portfolio and be prepared to make optimal use of our strong financial reserves. Our business development team has received expressions of interest from several multinational pharmaceutical companies, hoping to explore collaborations to advance the development and launch of innovative drug candidates with global market leadership potential. These potential collaborations will further validate the scientific value and commercial potential of our innovation platform, enabling HUTCHMED to leverage the expertise of partners in global development and marketing to accelerate the global advancement of innovative drugs to address unmet medical needs. FRUZAQLA has successfully validated this strategy, and we will also extend this strategy to our ATTC technology, expecting to see initial results within this year. Our company is at a critical turning point. We have adjusted the positioning of our commercial team to better respond to the current environmental challenges and promote sales growth in the Chinese market, with significant progress already seen in the second quarter of 2025. For our late-stage pipeline projects, our Phase III studies have yielded encouraging clinical results and support the submission of new drug applications for market approval. We have also accumulated significant experience in obtaining approvals from mainstream regulatory agencies. In addition, our large molecule technology platform has smoothly transitioned from the drug discovery stage to the clinical development stage, with two candidate drugs already in clinical trials. We believe this is a significant development opportunity for HUTCHMED, not only deepening our collaboration with top global industry players but also increasing research and development investment to accelerate the realization of the platform's vast therapeutic potential."